News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sanofi (France) (SAN.PA) Sues Eli Lilly and Company (LLY) Over Challenge To Top Diabetes Drug Lantus


1/31/2014 7:21:35 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

French drugmaker Sanofi is suing Eli Lilly and Co for alleged patent infringements concerning its top-selling Lantus diabetes treatment, delaying the U.S. firm's plans to produce a copycat version of Lantus. Lantus is the world's most prescribed insulin product, with annual worldwide sales of about $7 billion, but is set to lose patent protection in the United States, the world's largest pharmaceutical market, in February 2015. Sanofi's lawsuit, filed on Thursday, triggers an automatic 30-month stay of approval by the U.S. Food and Drug Administration (FDA), keeping Lilly's biosimilar drug off the U.S. market until mid-2016, more than a year later than its previously expected launch date.

Help employers find you! Check out all the jobs and post your resume.

Read at Reuters
Read at Nasdaq
Read at News Release
Read at AFP


comments powered by Disqus
Reuters
Nasdaq
News Release
AFP
   
Diabetes

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES